Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
5.38
+0.28 (5.49%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Tenax Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
192.89M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
TENX News
- 7 days ago - Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts - Seeking Alpha
- 23 days ago - Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Tenax Therapeutics Announces $25 Million Private Placement - GlobeNewsWire
- 7 weeks ago - Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF - GlobeNewsWire
- 7 weeks ago - Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - GlobeNewsWire
- 5 months ago - Tenax Therapeutics, Inc. (TENX) Guggenheim Healthcare Innovation Conference (Transcript) - Seeking Alpha